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Abstract 
Clinical trials are essential in neonates to evaluate scientifically the efficacy and safety of 
drugs. Neonatal specificities that induce specific obstacles in neonatal studies are 
detailed. This review looks also at new recommendations recently developed by the 
European Commission to promote a safe and ethical research in neonatology.   
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INTRODUCTION 
 
Clinical trials are essential to provide a safe, effective and evidence based medicine. In 
contrast, up to 90 % of drugs are used in an unauthorised and off-label manner in 
neonates with a greater risk of drug toxicity [1]. Actually, reserves to perform clinical 
trials in neonates are bound to physiological and ethical specifics. Indeed, neonatal 
studies encompass numerous obstacles of which the vulnerability and the incompetence 
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of this population, the technical difficulties, the uniqueness of neonatal diseases and the 
frequency of emergencies situations. Neonatology is a relatively new discipline that 
should largely benefit from clinical research but the fragility of neonatal subjects makes 
them highly vulnerable to experimental interventions. That’s why specific risks and limits 
of studies in neonatal period must be counter-balanced by both a strictly controlled but 
also incited research. Recently, the European Commission has edited recommendations 
on clinical trials in pediatrics in a way to regulate, promote and harmonize research in the 
european pediatric population [2]. This paper focuses on methodological and ethical 
problems specific to clinical trials in neonates.  
  
SAFETY AND RISK 
Children are not small adults and neonates are not small children. History of clinical 
research is full of dramatic examples that demonstrate the uniqueness of neonatal 
physiology. Risk/benefits equipoise must always be considered [3, 4]. 
Physiologic specificity of the neonates 
Neonates are the group of children from birth up to 28 days excluded, be they preterm or 
term. This transitional period is characterized with physiological immaturity of many 
organs or systems that could impact the pharmacokinetics, pharmacodynamics and finally 
the tolerance of drugs [5].  Cardiopulmonary changes are a critical event that could 
influence organ functions (renal blood flow, brain perfusion, hepatic metabolism). In 
preterm babies, many pathological situations (as patent ductus arteriosus or respiratory 
distress syndrome) can interfere with a trial protocol and have to be considered. Another 
aspect of neonatal specificity is brain development. Indeed, maturation of central nervous 
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system is a continuous process (glial multiplication) that completes long after birth (one 
year of age). This immaturity makes the brain more vulnerable so as autoregulation of 
cerebral blood flow is limited. Drugs can interact with neurotransmitters and lead to long 
term neurodevelopmental effects. In particular, drugs interacting with bilirubin 
metabolism should be carefully monitored. Renal function is also altered in neonates. 
Glomerular filtration is physiologically reduced. This impairment is accentuated by 
preterm birth (incomplete nephrogenesis before 34 weeks of post-menstrual age) or by 
ongoing disease or intrauterine growth retardation. So, the lower renal elimination 
capacity of neonates has to be considered and estimated both with post-natal and post-
menstrual ages. The pharmacokinetics of drugs can be also changed by hepatic and 
enzymatic immaturity that altered hepatic clearance as well as glucuronidation and 
enterohepatic recirculation. Moreover, the immaturity of gastrointestinal tract (high 
gastric pH, reduced pancreatic and biliary functions) can alter the bioavailability of orally 
administrated drugs and make it unpredictable. Gastrointestinal immaturity makes the 
preterm neonate more susceptible to necrotizing enterocolitis.  Lastly, associated diseases 
(respiratory distress syndrome, patent ductus arteriosus, necrotizing enterocolitis or 
retinopathy of prematurity) and conditions (prematurity or in utero growth restriction) 
can independently affect the pharmacokinetics and pharmacodynamics of drugs.  
Risks of clinical trials in neonates 
The immaturity of neonates associated with severe diseases that require multiple drugs 
administration increases the risk of iatrogenic events, drug interactions and adverse 
reactions. In a recent review, Sammons and colleagues evaluated the drug toxicity 
studying 739 pediatric clinical trials published over 7 years [6].  Seventy one percent of 
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trials reported adverse events and twenty percent reported serious adverse events. In 
eleven percent of the trials, moderate or severe adverse drug reactions (ADR) were 
present. Thirteen percent of trials involved neonates, but neonatal trials were 
overrepresented in studies with severe ADR (9 in 35 trials). The severe ADR included 
apnea, hypotension, gastrointestinal hemorrhage, ototoxicity and sepsis. Mortality was 
also higher in trials involving neonates even if mortality was often linked to the natural 
process of the disease. In two trials in neonates, mortality was higher in the treatment 
group. But surprisingly, the authors noticed that only 2 % of the trials had an independent 
safety monitoring committee as recommended in Europe. Another peculiarity of neonatal 
research is the necessity of long term follows up for safety. Indeed, many studies have 
shown that early infancy is a critical window for the programming of physiological 
changes. We have to consider the possibility of long term effects, in particular 
neurodevelopmental effects of drugs used in neonatal period. 
Pain and stress 
Many studies showed that repeated or prolonged exposure to pain or stress is an 
independent risk factor for brain damage and neurodevelopment impairment [7, 8]. 
Indeed, immature neurons and glial elements are vulnerable to apoptosis or excitotoxicity 
that may be favored by painful procedures. Limitation of stressing procedures (noise, 
light, blood sampling and investigations) must be a priority during clinical trials. Many 
validated non-invasive techniques (cardiac monitoring, transcutaneous measurement of 
pCO2, oxygen saturation from pulse oxymetry, cardiac and brain ultrasonography) can be 
used to evaluate clinical parameters. Pain has to be prevented, monitored using validated 
scales and adequately managed using pre-emptive treatment like sucrose or topical 
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anesthesia. The use of indwelling catheter (umbilical or arterial venous catheter) has to be 
considered when repeated blood samples are needed.  
 
TRIALS DESIGN: METHODOLOGY, LIMITS  
The specificity of neonatal period has been emphasized in the previous sections and 
summarized in table 1. The specificity of neonatal patients induces limitations in trials 
design that can be encompassed by methodological adaptations. 
Specific institutions f r specific patients 
Special patients need special trials by experienced centers. These imply a specific 
regulation and representation of pediatric and neonatal medicine in institutional review 
boards and ethics committees as well as a local specific institutional and administrative 
assistance with appropriate resources dedicated to neonatal clinical research. These 
conditions are essential to ensure optimal protection, respect and medical support adapted 
to neonates.  
Specific methods for specific patients 
Even if a relative homogeneity of patients and standardization of neonatal care are 
marked advantages in neonatal research, studies are limited by small samples of eligible 
patients and by a low number of perinatal centers. These obstacles can be by-passed by 
the optimization of design methods. Randomised, multicenter and blinded studies are the 
gold standard both for demonstration of efficacy and safety. In this vulnerable population, 
size sample should be as small as possible to demonstrate efficacy with sufficient 
statistical power. Adaptive bayesian sequential modeling or other models also developed 
in adults can be used to decrease the number of participants. Otherwise, the use of 
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placebo has to be discussed. The use of placebo is restricted compared to adults or 
children studies but can be considered in the case of poor or questionable efficacy or 
safety of the commonly used treatment. In particular in studies on analgesia, the use of 
placebo is not acceptable. A comparator group is ethically more acceptable and clinically 
more relevant even in case of off-label use if they are the standard of care. The technique 
of population pharmacokinetics based on lower blood samples in a larger population is 
interesting to limit both blood samples and bias linked to the maturating process and 
inter-individual variability.  Stratification by term gestation or birth weight of the trial 
population is often required to limit the influence of maturation process. Many antenatal 
(antenatal treatment, maternal diseases) and postnatal (drugs, patent ductus arteriosus, 
hemodynamic and respiratory status) conditions can affect outcome and require 
identification and careful analysis to limit bias. Relevant primary endpoints have to be 
described, based on harmonized definitions and assessed using validated procedures for 
judgment. The complications of prematurity (bronchopulmonary dysplasia, 
intraventricular haemorrhage, necrotizing enterocolitis, retinopathy of prematurity) and 
survival are classical secondary endpoints that need to be assessed. Lastly, we underline 
the importance of long-term physical and neurodevelopmental follow up to evaluate the 
long term impact of drugs in this maturating population. 
Specific drugs for specific patients 
Iatrogenic events are more frequent in neonates. These underline the importance of 
accurate choice of formulations and route of administration. First, they suffer more 
medication errors. The implication of drugs companies is essential to provide appropriate 
formulations in way to limit dilutions. Second, adverse drug reaction are more frequent 
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and more severe in neonates. Potential incompatibilities, excessive amounts of 
electrolytes, cutaneous or digestive tolerance must be considered. Finally, it is essential to 
re-adjust dosage of drugs over time according to actual weight and organ maturation of 
the neonate to maintain the best efficacy and safety. 
Volume of blood samples 
Preterm and term neonates have restricted blood volume (80 to 90 ml/Kg). Moreover, 
pathologic conditions increase blood loss and blood sampling necessity. 
Recommendations have been applied to limit trial-related blood loss. Micro-methods 
samples are required and limited to 2.4 ml blood per Kg body weight for the 3 % limit, 
over a 4-week period. Expected blood loss has to be detailed both in trial protocol and in 
parent information sheet. 
 
ETHICAL ISSUES 
Ethical principles in neonatal research are expressed in the Declaration of Helsinki and 
based on three foundations: respect for persons, beneficence and justice [9].  
Balance of risk and benefit 
Probability of benefits and potential risks need to be continuously balanced [10]. The 
neonate’s interest always prevails over that of science or society. Risk is classically 
divided into three categories: minimal, low or minor and high. Risk also depends on the 
invasiveness of the procedures and monitoring or the toxicity of the drugs. Benefit can be 
defined as a progress in safety or efficacy in treatment.  The risk/benefit balance must 
take into considerations the severity of the condition/disease studied, the vulnerability of 
the neonates and the expected improvement in comparison with an alternative existing 
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treatment. Non-therapeutic experiments with benefits for the neonatal population have a 
limited place in neonatal research and can only be considered if they cannot be performed 
in older children with minimal or low risk. As in adults, risk has to be continuously 
monitored using a Data and Safety Monitoring Board. Independent paediatric experts are 
recommended. 
Ethical committee’s composition 
Ethical committees are needed to provide an independent opinion on trial and on balance 
risk/benefits. The vulnerability and pharmacological peculiarities of neonates, the 
complexity and frequent emergency context of neonatal situations underline the 
importance to have a scrutiny scientific and ethical expertise of protocols. The 
committees must include paediatric physicians qualified in neonatal medicine and trained 
to clinical research as well as paediatric ethicists, pharmacologists or psychologists. In 
particular, they have to make sure that pain and stress induced by clinical research have 
been prevented and minimized [11]. They also must require minimal blood sampling 
[12].   
Parental consent 
As neonates can never obviously consent, the informed, voluntary and written consent of 
each legal representative of the neonate is ethically and legally required prior to 
enrollment. This consent meets the standards required in other consent. Information must 
be honest, adequate and must describe the aim and nature of the study, the expected 
benefits or potential risks, the name of investigators and contact details. The consent has 
to be given free from coercion. Sufficient time of thinking must be accorded and the 
possibility to revoke informed consent must be specified. Consent is a continuous process 
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that needs time and multiple discussions during the trial. In practice, many circumstances 
could interfere with those consent criteria. Many concepts like randomization can be 
misunderstood by parents. Emergencies situations are frequent and can disturb consent 
process, parent objectivity particularly when time available to consent is short and 
diseases are life-threatening. Relationship between parents and the physician of their 
children is also complex. This relation depends of many psychological, emotional, 
cultural and social circumstances as well as severity of the disease of their children that 
could affect their judgment and influence their reasons to consent. Otherwise, it can be 
occasionally hard to respect parent decision that seems to compromise the fundamental 
rights of the infant to beneficence. Clinical research in neonates points out many 
philosophical questions and limits of legislation [13-15]. The important is to obtain the 
best consent possible and to adjust information honestly in a continuous and dynamic 
process of assent [16].   
 
CONCLUSION 
Authorities have now realized the importance of development of clinical trials peculiar to 
children. Recommendations have been made to harmonized practices over Europe in a 
way to promote a safe and ethical research. Guidelines reflect positive evolutions and 
changes of our societies on clinical research in paediatric population. However, applying 
these paediatric guidelines to neonatal research is sometimes challenging. These 
difficulties underline the necessity of specific protective regulations on neonatal research. 
Let us hope that pharmaceutical industry supports these changes. 
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Table 1. Neonatal specificities that impact on trial design. 
 
 
• Organ/system immaturity 
• Frequency of emergency context 
• Limited number of eligible subjects and perinatal centers 
• Increased iatrogenic risk 
• Limited biologic sampling facilities and vascular access 
• Influence of developmental specifics on outcome measurements 
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